HIV and its effects on bone: A primer for rheumatologists

Current Opinion in Rheumatology

Volumn 24, Issue 5, 2012, Pages 567-575

  Gedmintas, Lydia ^a   Solomon, Daniel H ^a,b  

^a Division of Rheumatology   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Avascular necrosis; bone disease; fracture; HIV; osteoporosis

Indexed keywords

ABACAVIR; C REACTIVE PROTEIN; CALCIUM; DARUNAVIR; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; OSTEOCLAST DIFFERENTIATION FACTOR; SAQUINAVIR; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTHRITIS; AVASCULAR NECROSIS; BODY MASS; BONE DENSITY; BONE METABOLISM; COMORBIDITY; DISEASE ASSOCIATION; FOLLOW UP; FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MIXED INFECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOLOGY; RISK FACTOR; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANTI-HIV AGENTS; BONE DENSITY; BONE DISEASES; BONE DISEASES, METABOLIC; FRACTURES, BONE; HIV INFECTIONS; HUMANS; OSTEONECROSIS; OSTEOPOROSIS; RISK FACTORS;

EID: 84864867955     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328356d266     Document Type: Review

References (50)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174.
2. Vikulina T, Fan X, Yamaguchi M, et al. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci USA 2010; 107:13848-13853.
3. Yin MT,McMahon DJ, Ferris DC, et al. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2010; 95:620-629.
4. Yin MT, Zhang CA, McMahon DJ, et al. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab 2011; 97:554-562.
5. Bolland MJ, Grey AB, Gamble GD, Reid IR. Clinical review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 2007; 92:4522-4528.
6. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23:1519-1529.
7. Hansen AB, Obel N, Nielsen H, et al. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitorsparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 2011; 12:157-165.
8. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-1801.
9. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-972.
10. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir preexposure prophylaxis randomized clinical trial in San Francisco. PLoS One 2011; 6:e23688.
11. Bonjoch A, Figueras M, Estany C, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010; 24:2827-2833.
12. Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200:1746-1754.
13. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23:817-824.
14. Bolland MJ, Grey A, Horne AM, et al. Stable bone mineral density over six years in HIV-infected men treated with highly active antiretroviral therapy (HAART). Clin Endocrinol (Oxf) 2011. doi: 10.1111/j.1365-2265.2011.04274.x.
15. Bolland MJ, Wang TK, Grey A, et al. Stable bone density in HAART-treated individuals with HIV: a meta-analysis. J Clin Endocrinol Metab 2007; 96:2721-2731.
16. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
17. Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011; 6:e17217.
18. Yin MT, Shi Q, Hoover DR, et al. Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS 2010; 24:2679-2686.
19. Yong MK, Elliott JH, Woolley IJ, Hoy JF. Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr 2011; 57:205-210.
20. Mundy LM, Youk AO, McComsey GA, Bowlin SJ. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. AIDS 2012 [Epub ahead of print].
21. Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012 [Epub ahead of print].
22. Hansen AB, Gerstoft J, Kronborg G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish populationbased cohort study. AIDS 2011; 26:285-293.
23. Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-1068.
24. Childs K, Welz T, Samarawickrama A, Post FA. Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients. AIDS 2012; 26:253-262.
25. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923-1928.
26. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIVinfected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52:396-405.
27. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 2010; 15:425-429.
28. Rosenvinge MM, Gedela K, Copas AJ, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr 2010; 54:496-499.
29. Masia M, Padilla S, Robledano C, et al. Short communication: early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses 2012; 28:242-246.
30. Havens PL, Stephensen CB, Hazra R, et al. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis 2012; 54:1013-1025.
31. Arpadi SM, McMahon DJ, Abrams EJ, et al. Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial. Am J Clin Nutr 2012; 95:678-685.
32. Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005; 38:426-431.
33. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007; 21:2473-2482.
34. Bolland MJ, Grey AB, Horne AM, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 2007; 92:1283-1288.
35. Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009; 23:51-57.
36. Mary-Krause M, Billaud E, Poizot-Martin I, et al. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. AIDS 2006; 20:1627-1635.
37. Ho YC, Shih TT, Lin YH, et al. Osteonecrosis in patients with human immunodeficiency virus type 1 infection in Taiwan. Jpn J Infect Dis 2007; 60:382-386.
38. Martin K, Lawson-Ayayi S, Miremont-Salame G, et al. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002). HIV Med 2004; 5:421-426.
39. Yamaguchi R, Yamamoto T, Motomura G, et al. Incidence of nontraumatic osteonecrosis of the femoral head in the Japanese population. Arthritis Rheum 2011; 63:3169-3173.
40. Bauer M, Thabault P, Estok D, et al. Low-dose corticosteroids and avascular necrosis of the hip and knee. Pharmacoepidemiol Drug Saf 2000; 9:187-191.
41. Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137:17-25.
42. Bongiovanni M, Chiesa E, Riva A, et al. Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavir. Int J Antimicrob Agents 2003; 22:630-631.
43. Meyer D, Behrens G, Schmidt RE, Stoll M. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors. AIDS 1999; 13:1147-1148.
44. Glesby MJ, Hoover DR, Vaamonde CM. Osteonecrosis in patients infected with human immunodeficiency virus: a case-control study. J Infect Dis 2001; 184:519-523.
45. Scribner AN, Troia-Cancio PV, Cox BA, et al. Osteonecrosis in HIV: a casecontrol study. J Acquir Immune Defic Syndr 2000; 25:19-25.
46. Schett G. Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009; 11:210.
47. Schett G, Kiechl S, Weger S, et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006; 166:2495-2501.
48. Keating SM, Golub ET, Nowicki M, et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS 2011; 25:1823-1832.
49. Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64-70.
50. Ofotokun I, McIntosh E, Weitzmann MN. HIV: inflammation and bone. Curr HIV/AIDS Rep 2011; 9:16-25.